{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T10:09:34Z","timestamp":1775470174902,"version":"3.50.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,3,18]],"date-time":"2019-03-18T00:00:00Z","timestamp":1552867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2019,3,18]],"date-time":"2019-03-18T00:00:00Z","timestamp":1552867200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s10637-019-00761-z","type":"journal-article","created":{"date-parts":[[2019,3,18]],"date-time":"2019-03-18T08:03:23Z","timestamp":1552896203000},"page":"20-28","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Knockdown of FBXO22 inhibits melanoma cell migration, invasion and angiogenesis via the HIF-1\u03b1\/VEGF pathway"],"prefix":"10.1007","volume":"38","author":[{"given":"Yufan","family":"Zheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hairong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinjin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1524-7893","authenticated-orcid":false,"given":"Jin","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,3,18]]},"reference":[{"issue":"5","key":"761_CR1","first-page":"277","volume":"60","author":"RL Siegel","year":"2015","unstructured":"Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA Cancer J Clin 60(5):277\u2013300","journal-title":"CA Cancer J Clin"},{"issue":"9919","key":"761_CR2","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/S0140-6736(13)60802-8","volume":"383","author":"AM Eggermont","year":"2014","unstructured":"Eggermont AM, Spatz A, Robert C (2014) Cutaneous melanoma. Lancet 383(9919):816\u2013827","journal-title":"Lancet"},{"issue":"36","key":"761_CR3","doi-asserted-by":"publisher","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","volume":"27","author":"CM Balch","year":"2009","unstructured":"Balch CM, Gershenwald JE, Soong S, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27(36):6199\u20136206","journal-title":"J Clin Oncol"},{"issue":"4","key":"761_CR4","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1200\/JCO.2007.12.7837","volume":"26","author":"EL Korn","year":"2008","unstructured":"Korn EL, Liu PY, Lee SJ, Chapman JAW, Niedzwiecki D, Suman VJ, Moon J, Sondak VK, Atkins MB, Eisenhauer EA (2008) Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol Off J Am Soc Clin Oncol 26(4):527\u2013534","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"1","key":"761_CR5","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/pcmr.12041","volume":"26","author":"JL Orgaz","year":"2013","unstructured":"Orgaz JL, Sanzmoreno V (2013) Emerging molecular targets in melanoma invasion and metastasis. Pigment Cell Melanoma Res 26(1):39\u201357","journal-title":"Pigment Cell Melanoma Res"},{"issue":"12","key":"761_CR6","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1038\/nrd4432","volume":"13","author":"JR Skaar","year":"2014","unstructured":"Skaar JR, Pagan JK, Pagano M (2014) SCF ubiquitin ligase targeted therapies. Nat Rev Drug Discov 13(12):889\u2013903","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"761_CR7","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/nrc3700","volume":"14","author":"PL Z W","year":"2014","unstructured":"Z W PL, H I WW (2014) Roles of F-box proteins in cancer. Nat Rev Cancer 14(4):233","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"761_CR8","doi-asserted-by":"crossref","first-page":"7179","DOI":"10.18632\/oncotarget.6886","volume":"7","author":"Z Luo","year":"2016","unstructured":"Luo Z, Zhang X, Zeng W, Su J, Yang K, Lu L, Lim CB, Tang W, Wu L, Zhao S (2016) TRAF6 regulates melanoma invasion and metastasis through ubiquitination of Basigin. Oncotarget 7(6):7179\u20137192","journal-title":"Oncotarget"},{"issue":"1","key":"761_CR9","doi-asserted-by":"publisher","first-page":"212","DOI":"10.3390\/ijms18010212","volume":"18","author":"B Wu","year":"2017","unstructured":"Wu B, Liu Z, Cui J, Yang X, Jing L, Zhou Y, Chen Z, Jiang J (2017) F-box protein FBXO22 mediates Polyubiquitination and degradation of CD147 to reverse cisplatin resistance of tumor cells. Int J Mol Sci 18(1):212","journal-title":"Int J Mol Sci"},{"issue":"1","key":"761_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbcan.2011.02.001","volume":"1816","author":"K Nys","year":"2011","unstructured":"Nys K, Maes H, Dudek AM, Agostinis P (2011) Uncovering the role of hypoxia inducible factor-1\u03b1 in skin carcinogenesis. Biochim Biophys Acta Rev Cancer 1816(1):1\u201312","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"6","key":"761_CR11","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.ccr.2005.11.005","volume":"8","author":"B Bedogni","year":"2005","unstructured":"Bedogni B, Welford SM, Cassarino DS, Nickoloff BJ, Giaccia AJ, Powell MB (2005) The hypoxic microenvironment of the skin contributes to Akt-mediated melanocyte transformation. Cancer Cell 8(6):443\u2013454","journal-title":"Cancer Cell"},{"issue":"6","key":"761_CR12","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/j.ejca.2010.01.031","volume":"46","author":"S Kuphal","year":"2010","unstructured":"Kuphal S, Winklmeier A, Warnecke C, Bosserhoff AK (2010) Constitutive HIF-1 activity in malignant melanoma. Eur J Cancer 46(6):1159\u20131169","journal-title":"Eur J Cancer"},{"issue":"2","key":"761_CR13","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.canlet.2006.08.016","volume":"249","author":"B Sun","year":"2015","unstructured":"Sun B, Zhang D, Zhang S, Zhang W, Guo H, Zhao X (2015) Hypoxia influences vasculogenic mimicry channel formation and tumor invasion-related protein expression in melanoma. Cancer Lett 249(2):188\u2013197","journal-title":"Cancer Lett"},{"issue":"5","key":"761_CR14","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1097\/00008390-200310000-00008","volume":"13","author":"A Giatromanolaki","year":"2003","unstructured":"Giatromanolaki A, Sivridis E, Kouskoukis C, Gatter KC, Harris AL, Koukourakis MI (2003) Hypoxia-inducible factors 1alpha and 2alpha are related to vascular endothelial growth factor expression and a poorer prognosis in nodular malignant melanomas of the skin. Melanoma Res 13(5):493\u2013501","journal-title":"Melanoma Res"},{"issue":"2","key":"761_CR15","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1158\/0008-5472.CAN-17-0883","volume":"78","author":"P Hou","year":"2018","unstructured":"Hou P, Li L, Chen F, Chen Y, Liu H, Li J, Bai J, Zheng J (2018) PTBP3-mediated regulation of ZEB1 mRNA stability promotes epithelial-mesenchymal transition in breast Cancer. Cancer Res 78(2):387\u2013398. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-0883","journal-title":"Cancer Res"},{"issue":"18","key":"761_CR16","doi-asserted-by":"publisher","first-page":"3687","DOI":"10.1128\/MCB.05746-11","volume":"31","author":"MM Tan","year":"2011","unstructured":"Tan MM, Lim H, Harper JW (2011) SCFFBXO22 regulates histone H3 lysine 9 and 36 methylation levels by targeting histone demethylase KDM4A for ubiquitin-mediated proteasomal degradation. Mol Cell Biol 31(18):3687\u20133699","journal-title":"Mol Cell Biol"},{"issue":"26","key":"761_CR17","doi-asserted-by":"publisher","first-page":"22767","DOI":"10.18632\/oncotarget.4082","volume":"6","author":"X Tian","year":"2015","unstructured":"Tian X, Dai S, Sun J, Jin G, Jiang S, Meng F, Li Y, Wu D, Jiang Y (2015) F-box protein FBXO22 mediates polyubiquitination and degradation of KLF4 to promote hepatocellular carcinoma progression. Oncotarget 6(26):22767\u201322775","journal-title":"Oncotarget"},{"issue":"7","key":"761_CR18","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/S0092-8674(03)00468-9","volume":"113","author":"RO Hynes","year":"2003","unstructured":"Hynes RO (2003) Metastatic potential: generic predisposition of the primary tumor or rare, metastatic variants-or both? Cell 113(7):821\u2013823","journal-title":"Cell"},{"issue":"2","key":"761_CR19","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.cell.2011.09.024","volume":"147","author":"S Valastyan","year":"2011","unstructured":"Valastyan S, Weinberg RA (2011) Tumor metastasis: molecular insights and evolving paradigms. Cell 147(2):275\u2013292","journal-title":"Cell"},{"issue":"407","key":"761_CR20","doi-asserted-by":"publisher","first-page":"cm8","DOI":"10.1126\/stke.4072007cm8","volume":"2007","author":"G. L. Semenza","year":"2007","unstructured":"Semenza GL (2007) Hypoxia-inducible factor 1 (HIF-1) pathway. Sciences Stke signal transduction knowledge environment 2007 (407):cm8","journal-title":"Science's STKE"},{"issue":"5","key":"761_CR21","first-page":"423","volume":"33","author":"Q Ke","year":"2005","unstructured":"Ke Q, Costa M (2005) Hypoxia-inducible Factor-1 (HIF-1). Crit Care Med 33(5):423\u2013425","journal-title":"Crit Care Med"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-019-00761-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-019-00761-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-019-00761-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T18:40:55Z","timestamp":1678560055000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-019-00761-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,18]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["761"],"URL":"https:\/\/doi.org\/10.1007\/s10637-019-00761-z","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,18]]},"assertion":[{"value":"3 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors have declared that no competing interest exists.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All experiments involved in this study were approved by both the Institutional Review Boards of Xuzhou Medical University and the Ethics Committee of the above hospital.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Each patient provided a written informed consent prior to the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}